ASH 2021 | Key MDS updates from the 2021 ASH meeting
Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, gives an overview of the latest research and updates in myelodysplastic syndromes (MDS) presented at ASH 2021. To begin with, the eagerly awaited results from the PANTHER study (NCT03268954) showed that the combination of pevonedistat and azacitidine did not lead to a significant improvement in complete response (CR) rate, event-free survival (EFS) and overall survival (OS) compared to azacitidine alone. Updates on other clinical trials evaluating frontline azacitidine plus venetoclax in different disease settings as well as APR-246 plus azacitidine in TP53-mutant MDS (NCT03072043) were also presented. Dr Zeidan also highlights promising data on the use of CPX-351 in MDS. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
